PARIS (Reuters) – Sanofi on Thursday confirmed its full-year profit forecast after a first quarter buoyed by the continued success of its drug Dupixent, sales of vaccines and those of the consumer healthcare division.
The group is still expecting net earnings per share (EPS) from activities to rise at constant exchange rates by a percentage “in the low single-digit range” (i.e. around 1%), a forecast which had disappointed investors when the annual results are announced at the beginning of February.
On the other hand, the impact of exchange rate effects on EPS was revised to a range of -5.5% to -6.5%, compared to around -3.5% to -4.5%.
In the first quarter, business EPS increased by 11.9% at constant exchange rates, and net sales by 5.5%, to 10.22 billion euros.
Sales of vaccines increased by 15.2%, those of consumer health by 11.2% while revenues from general medicine fell by 11.4%.
Sales of Dupixent, a treatment used in particular for atopic dermatitis, climbed 39.7%.
“Dupixent continues its strong performance and is on track to reach the target of 10 billion euros in sales for this year,” said CEO Paul Hudson in a statement.
“We are confident in our business prospects for the remainder of the year, while managing our last significant loss of exclusivity of the decade with the entry into the US market at the end of the first quarter of Aubagio’s generics. “, he added.
(Written by Blandine Hénault, edited by Kate Entringer)
Copyright © 2023 Thomson Reuters
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
